FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World
This article was originally published in RPM Report
Executive Summary
The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.
You may also be interested in...
Avandia: How do you hold a moon beam in your hand?
FDA faces a tough decision on Avandia. Should it stay or should it go? There is bigger underlying issue: should the standard be different for pulling a drug than it is for approving the drug in the first place? It may be counterintuitive, but a different standard makes sense.
Drug Safety in Post-FDAAA Era: An Epidemiologist's View
Bruce Psaty, longtime advocate of increased post-market safety controls for drugs, sees big challenges looming for FDA as it tries to adapt to the new authorities granted by the 2007 Food & Drug Administration Amendments Act. Psaty views the establishment of a large 100-million-life post-market surveillance system as a particularly daunting challenge.
Avandia's Black Box: FDA's Office of New Drugs Wins
The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.